Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment goals in irritable bowel syndrome
Autore:
Kellow, JE;
Indirizzi:
Univ Sydney, Royal N Shore Hosp, Dept Gastroenterol, St Leonards, NSW 2065, Australia Univ Sydney St Leonards NSW Australia 2065 Leonards, NSW 2065, Australia
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 8, volume: 55, anno: 2001,
pagine: 546 - 551
SICI:
1368-5031(200110)55:8<546:TGIIBS>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTROLLED TREATMENT TRIALS; QUALITY-OF-LIFE; GUT; MANAGEMENT; MOTILITY; DISORDERS; SENSATION; ARTICLE; 5-HYDROXYTRYPTAMINE; SENSITIVITY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Kellow, JE Univ Sydney, Royal N Shore Hosp, Dept Gastroenterol, St Leonards, NSW 2065, Australia Univ Sydney St Leonards NSW Australia 2065 NSW 2065, Australia
Citazione:
J.E. Kellow, "Treatment goals in irritable bowel syndrome", INT J CL PR, 55(8), 2001, pp. 546-551

Abstract

Irritable bowel syndrome (IBS) carries a considerable economic and social impact which may, in part, be due to inefficient diagnosis and inappropriate treatment choice leading to continued patient ill health and absenteeism. Even assuming that IBS can be diagnosed positively, using well-establishedsymptom-based criteria, management difficulties remain. Thus, pharmacological treatment choice is still based on the single predominant symptom, and many currently available treatments are ineffective in the long term. A greater understanding of the pathophysiology of IBS may lead to the development of more effective treatments that can target the multiple symptoms present in IBS. A new understanding of the role of serotonin (5-HT) and specific receptors (5-HT3 and 5-HT4) found in the gastrointestinal (GI) tract has led to the development of serotonergic agents which have potential clinical benefits. Recent clinical trials suggest that 5-HT4 receptor partial agonists, in particular, may have the ability to offer multiple symptom relief, without the risk of significant adverse reactions.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 04:45:55